Dr. Jeffrey S. Dover, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 545
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
MA license 55225
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Skincare Physicians Inc (17 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 545
- Services billed
- 3,953
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 849 | 144 |
| Established patient office or other outpatient visit, 20-29 minutes | 510 | 365 |
| Destruction of precancer skin growth, 1 growth | 256 | 183 |
| Destruction of skin growth, 1-14 growths | 246 | 190 |
| Established patient office or other outpatient visit, 30-39 minutes | 109 | 95 |
| Biopsy of related skin growth, first growth | 93 | 85 |
| Established patient office or other outpatient visit, 10-19 minutes | 81 | 68 |
| New patient office or other outpatient visit, 30-44 minutes | 71 | 71 |
| Destruction of precancer skin growth, 15 or more growths | 33 | 25 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 30 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ketoconazole Other prescribers in Chestnut Hill, MA | 47 |
| Clobetasol Propionate Other prescribers in Chestnut Hill, MA | 30 |
| Triamcinolone Acetonide Other prescribers in Chestnut Hill, MA | 30 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Chestnut Hill, MA | 18 |
| Metronidazole Other prescribers in Chestnut Hill, MA | 16 |
| Dupixent Pen (dupilumab) Other prescribers in Chestnut Hill, MA | 14 |
| Doxycycline Hyclate Other prescribers in Chestnut Hill, MA | 14 |
| Seysara (sarecycline hcl) | 12 |
| Minoxidil Other prescribers in Chestnut Hill, MA | 11 |
| Betamethasone Dipropionate Other prescribers in Chestnut Hill, MA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 9 payments worth $28,154 in total to this clinician.
| Solta Medical, A Division of Bausch Health US, LLC | $24,655 |
|---|---|
| Revance Therapeutics, Inc. | $2,522 |
| AbbVie Inc. | $890 |
| Galderma Laboratories, L.P. | $71.13 |
| Sun Pharmaceutical Industries Inc. | $16.07 |
| Compensation for services other than consulting (speaking, faculty) | $19,905 |
|---|---|
| Consulting Fee | $8,140 |
| Food and Beverage | $109 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Solta Medical, A Division of Bausch Health US, LLC Aug 6, 2025 | Compensation for services other than consulting (speaking, faculty) | $14,250 |
| Solta Medical, A Division of Bausch Health US, LLC Jan 29, 2025 | Compensation for services other than consulting (speaking, faculty) CLEAR+BRILLIANT | $5,655 |
| Solta Medical, A Division of Bausch Health US, LLC Sep 24, 2025 | Consulting Fee | $4,750 |
| Revance Therapeutics, Inc. Aug 28, 2025 | Consulting Fee DAXXIFY · AESTHETICS AND THERAPEUTICS | $2,500 |
| AbbVie Inc. Sep 17, 2025 | Consulting Fee | $890 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $341,853 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
AbbVie Inc. · Completed · NCT06834789
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.